Vir Biotechnology Inc (VIR)

NASDAQ
28.41
+0.56(+2.03%)
  • Volume:
    241,190
  • Day's Range:
    27.58 - 28.55
  • 52 wk Range:
    18.21 - 58.00

VIR Overview

Prev. Close
27.85
Day's Range
27.58-28.55
Revenue
2.11B
Open
28.32
52 wk Range
18.21-58
EPS
8.19
Volume
241,190
Market Cap
3.76B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
968,738
P/E Ratio
3.88
Beta
-0.406
1-Year Change
-28.86%
Shares Outstanding
132,637,878
Next Earnings Date
Nov 03, 2022
What is your sentiment on Vir Biotech?
or
Vote to see community's results!

Vir Biotechnology Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Vir Biotechnology Inc Analysis

Vir Biotechnology Inc Company Profile

Vir Biotechnology Inc Company Profile

Employees
444

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellSellBuy
Technical IndicatorsStrong BuyStrong BuyStrong SellNeutralStrong Sell
SummaryStrong BuyBuyStrong SellNeutralNeutral
  • Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $45
    0
    • While waiting for the catalyst, $35 was added. Flying to the moon is a matter of time 🚀🤑
      0
      • Dear Brother from Bulgaria, when will rise the price do you have any opinion please ?
        0
    • On Monday Bull ran?
      0
      • Hi there,I have been having a look on this company and its numbers seem quite good isn´t?Here in Europe turned up the new about GSK and sotrovimab,apparently this treatment works(apparently....)and seeing the crash that happened yesterday with Vir and the pre market looks a good day to get in.If anyone had any other info I would really appreciate if shared it.Regards
        0
        • It's the worst stock I ever hold... I only hope it will shoot on new data on Omicron
          1
          • Do anyone know why VIR surged more than 40% over the past 3 days? New therapeutic product or treatment developed in regards to Omicron variant?
            0
            • Some times later, you will see price of 200. When? There is no information,but its important to buy on time.
              0
              • Expect back to 40s
                1
                • on Monday BULL RUN
                  0
                  • now invest in vir
                    0